Ora Biomedical, Inc., a pioneering longevity biotechnology firm, is happy to announce that it has been awarded a Small Enterprise Innovation Analysis (SBIR) Section I grant from the Nationwide Institutes of Well being (NIH). The $324,240 grant will assist the event of EleGantry, an modern software program and {hardware} infrastructure designed to boost rigor and reproducibility in invertebrate analysis, with a specific give attention to longevity research utilizing Caenorhabditis elegans (C. elegans).
EleGantry: Revolutionizing Preclinical Drug Discovery
Ora Biomedical focuses on discovering and growing interventions that reach wholesome lifespan and fight age-associated ailments by concentrating on the elemental mechanisms of organic getting older. The EleGantry system represents a big development within the firm’s high-throughput drug discovery pipeline. By automating key steps within the C. elegans analysis course of and enhancing information assortment throughout your entire lifespan, EleGantry will tackle the rising want for elevated rigor and reproducibility in preclinical research.
“With the NIH’s assist, we’re poised to determine and overcome main sources of variability and challenges related to C. elegans analysis, contributing to our objective of making the world’s largest and highest high quality longevity interventions database,” stated Dr. Mitchell Lee, CEO of Ora Biomedical. “EleGantry is not going to solely elevate the usual of preclinical getting older analysis but in addition
expedite improvement of sturdy therapeutics that may considerably prolong wholesome human lifespan.”
Why EleGantry Issues
C. elegans has lengthy been a mainstay in biomedical getting older analysis as a result of extremely evolutionarily conserved options drive getting older from invertebrates to mammals. Nevertheless, variability in analysis methodologies has usually led to inconsistent outcomes, significantly in research centered on lifespan. EleGantry will mitigate these points by integrating superior imaging, information assortment, and evaluation instruments powered by state-of-the-art machine studying algorithms. The platform can even automate information reporting, making it simpler for researchers to duplicate research and validate findings. Ora Biomedical’s pioneering work on this subject advances non-mammal animal fashions for drug improvement and aligns carefully with the FDA Modernization Act 2.0 which goals to cut back using reside mammals in analysis.
“The event of EleGantry is essential as we transfer in the direction of extra dependable and scalable invertebrate fashions for drug discovery,” added Dr. Lee. “This software will allow us to determine and prioritize therapeutic leads with unprecedented effectivity and accuracy.”
Wanting Forward
The profitable completion of this Section I undertaking will pave the best way for the next improvement and commercialization of EleGantry, additional establishing Ora Biomedical as a pacesetter in longevity biotechnology. The corporate plans to make use of EleGantry to develop its preclinical screening capabilities, offering a sturdy platform for locating the subsequent technology of gerotherapeutics. This undertaking is supported by the Workplace Of The Director, Nationwide Institutes Of Well being and the Nationwide Institute of Normal Medical Sciences (NIGMS), below Award Quantity R43OD037622. The content material is solely the duty of the authors and doesn’t essentially symbolize the official views of the Nationwide Institutes of Well being.
About Ora Biomedical
Ora Biomedical, Inc. is a long life biotechnology firm headquartered in Tukwila, WA. Launched out of the College of Washington College of Drugs in 2022, Ora Biomedical develops interventions that maximize wholesome lifespan by concentrating on the molecular mechanisms that drive getting older itself. Ora makes use of best-in-class robotics and AI to carry out high-throughput, high-precision phenotypic testing in reside animals with lifespan, healthspan, and stress resistance as main endpoints.
Firm Press Contact:
Dr. Mitchell Lee
CEO & Co-Founder, Ora Biomedical, Inc.
E-mail: [email protected]
